PRESS RELEASE published on 08/30/2023 at 14:30, 2 years 8 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 2 years 8 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 2 years 8 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 2 years 8 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 2 years 8 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
PRESS RELEASE published on 08/14/2023 at 14:00, 2 years 8 months ago Jaguar Health Reports Second Quarter 2023 Financial Results
PRESS RELEASE published on 08/10/2023 at 14:30, 2 years 8 months ago Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
PRESS RELEASE published on 08/09/2023 at 14:30, 2 years 9 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 08/08/2023 at 14:30, 2 years 9 months ago Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
PRESS RELEASE published on 08/07/2023 at 14:30, 2 years 9 months ago Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published on 05/09/2026 at 01:30, 1 day 12 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 13 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 11:45, 2 hours 10 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 18 hours 50 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 17 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 18 hours ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 18 hours ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days 18 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 18 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 18 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 18 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 18 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
